Karin Dijkman

Karin Dijkman

Auto-generated profile, based on publicly available information

Karin Dijkman

Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
KDKarin Dijkman
Karin Dijkman
CSClaudia C. Sombroek
Claudia C. Sombroek
RVRichard A. W. Vervenne
Richard A. W. Vervenne
SHSam O. Hofman
Sam O. Hofman
CBCharelle Boot
Charelle Boot
FVFrank Verreck
Frank Verreck

18 November 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
JWJoshua S. Woodworth
Joshua S. Woodworth
HCHelena Strand Clemmensen
Helena Strand Clemmensen
HBHannah Battey
Hannah Battey
KDKarin Dijkman
Karin Dijkman
TLThomas Lindenstrøm
Thomas Lindenstrøm
RMRasmus S. Mortensen
Rasmus S. Mortensen
Given the encouraging clinical results of both candidate subunit vaccines and revaccination with Bacillus Calmette-Guérin (BCG) against tuberculosis (TB), there is support for combining BCG and subunit vaccination for increased efficacy. BCG and Mycobacterium tuberculosis (Mtb) share ~98% of their genome and current subunit vaccines are almost exclusively designed as BCG boosters. The goal of this study is to design a TB subunit vaccine composed of antigens not shared with BCG and explore the advantages of this design in a BCG + subunit co-administration vaccine strategy. Eight protective antigens are selected to create an Mtb-specific subunit vaccine, named H107. Whereas traditional vaccines containing BCG-shared antigens exhibit in vivo cross-reactivity to BCG, H107 shows no cross-reactivity and does not inhibit BCG colonization. Instead, co-administering H107 with BCG leads to increased adaptive responses against both H107 and BCG. Importantly, rather than expanding BCG-primed T cells, H107 broadens the overall vaccine repertoire with new T cell clones and introduces ‘adjuvant-imprinted’ qualities including Th17 responses and less-differentiated Th1 cells. Collectively, these features of H107 are associated with a substantial increase in long-term protection.

1 January 2013 in Molecular Immunology
Verified
Journal Article
Closed access
MLMargit Lampen
Margit Lampen
CHChopie Hassan
Chopie Hassan
MSMarjolein Sluijter
Marjolein Sluijter
AGAnnemieke Geluk
Annemieke Geluk
KDKarin Dijkman
Karin Dijkman
THThorbald van Hall
Thorbald van Hall

15 February 2013 in The Journal of Immunology
Verified
Journal Article
Closed access
SCSusanna Commandeur
Susanna Commandeur
KMKrista E van Meijgaarden
Krista E van Meijgaarden
CPCorine Prins
Corine Prins
APAlexander V Pichugin
Alexander V Pichugin
KDKarin Dijkman
Karin Dijkman
TOTom H M Ottenhoff
Tom H M Ottenhoff
Mycobacterium tuberculosis is responsible for almost 2 million deaths annually. Mycobacterium bovis bacillus Calmette-Guérin, the only vaccine available against tuberculosis (TB), induces highly variable protection against TB, and better TB vaccines are urgently needed. A prerequisite for candidate vaccine Ags is that they are immunogenic and expressed by M. tuberculosis during infection of the primary target organ, that is, the lungs of susceptible individuals. In search of new TB vaccine candidate Ags, we have used a genome-wide, unbiased Ag discovery approach to investigate the in vivo expression of 2170 M. tuberculosis genes during M. tuberculosis infection in the lungs of mice. Four genetically related but distinct mouse strains were studied, representing a spectrum of TB susceptibility controlled by the supersusceptibility to TB 1 locus. We used stringent selection approaches to select in vivo–expressed M. tuberculosis (IVE-TB) genes and analyzed their expression patterns in distinct disease phenotypes such as necrosis and granuloma formation. To study the vaccine potential of these proteins, we analyzed their immunogenicity. Several M. tuberculosis proteins were recognized by immune cells from tuberculin skin test-positive, ESAT6/CFP10-responsive individuals, indicating that these Ags are presented during natural M. tuberculosis infection. Furthermore, TB patients also showed responses toward IVE-TB Ags, albeit lower than tuberculin skin test-positive, ESAT6/CFP10-responsive individuals. Finally, IVE-TB Ags induced strong IFN-γ+/TNF-α+ CD8+ and TNF-α+/IL-2+ CD154+/CD4+ T cell responses in PBMC from long-term latently M. tuberculosis–infected individuals. In conclusion, these IVE-TB Ags are expressed during pulmonary infection in vivo, are immunogenic, induce strong T cell responses in long-term latently M. tuberculosis–infected individuals, and may therefore represent attractive Ags for new TB vaccines.

27 December 2013 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
AGand Annemieke Geluk
and Annemieke Geluk
KMKrista E. van Meijgaarden
Krista E. van Meijgaarden
LWLouis Wilson
Louis Wilson
KBKidist Bobosha
Kidist Bobosha
JSJolien J. van der Ploeg-Van Schip
Jolien J. van der Ploeg-Van Schip
TOTom H. M. Ottenhoff
Tom H. M. Ottenhoff

8 May 2014 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
KBKidist Bobosha
Kidist Bobosha
EFElisa M. Tjon Kon Fat
Elisa M. Tjon Kon Fat
SESusan J. F. van Den Eeden
Susan J. F. van Den Eeden
YBYonas Bekele
Yonas Bekele
JSJolien J. van der Ploeg-Van Schip
Jolien J. van der Ploeg-Van Schip
AGand Annemieke Geluk
and Annemieke Geluk
Field-applicable tests detecting asymptomatic Mycobacterium leprae (M. leprae) infection or predicting progression to leprosy, are urgently required. Since the outcome of M. leprae infection is determined by cellular- and humoral immunity, we aim to develop diagnostic tests detecting pro-/anti-inflammatory and regulatory cytokines as well as antibodies against M. leprae. Previously, we developed lateral flow assays (LFA) for detection of cytokines and anti-PGL-I antibodies. Here we evaluate progress of newly developed LFAs for applications in resource-poor settings. The combined diagnostic value of IP-10, IL-10 and anti-PGL-I antibodies was tested using M. leprae-stimulated blood of leprosy patients and endemic controls (EC). For reduction of the overall test-to-result time the minimal whole blood assay time required to detect distinctive responses was investigated. To accommodate LFAs for field settings, dry-format LFAs for IP-10 and anti-PGL-I antibodies were developed allowing storage and shipment at ambient temperatures. Additionally, a multiplex LFA-format was applied for simultaneous detection of anti-PGL-I antibodies and IP-10. For improved sensitivity and quantitation upconverting phosphor (UCP) reporter technology was applied in all LFAs. Single and multiplex UCP-LFAs correlated well with ELISAs. The performance of dry reagent assays and portable, lightweight UCP-LF strip readers indicated excellent field-robustness. Notably, detection of IP-10 levels in stimulated samples allowed a reduction of the whole blood assay time from 24 h to 6 h. Moreover, IP-10/IL-10 ratios in unstimulated plasma differed significantly between patients and EC, indicating the feasibility to identify M. leprae infection in endemic areas. Dry-format UCP-LFAs are low-tech, robust assays allowing detection of relevant cytokines and antibodies in response to M. leprae in the field. The high levels of IP-10 and the required shorter whole blood assay time, render this cytokine useful to discriminate between leprosy patients and EC. Leprosy is one of the six diseases considered by WHO as a major threat in developing countries and often results in severe, life-long disabilities and deformities due to delayed diagnosis. Early detection of Mycobacterium leprae (M. leprae) infection, followed by effective interventions, is considered vital to interrupt transmission. Thus, field-friendly tests that detect asymptomatic M. leprae infection are urgently required. The clinical outcome after M. leprae infection is determined by the balance of pro- and anti-inflammatory cytokines and antibodies in response to M. leprae. In this study, we developed lateral flow assays (LFA) for detection of pro-inflammatory (IP-10) vs. anti-inflammatory/regulatory (IL-10) cellular immunity as well as antibodies against M. leprae and evaluated these in a field setting in Ethiopia using lightweight, portable readers. We show that detection of IP-10 allowed a significant reduction of the overall test-to-result time from 24 h to 6 h. Moreover, IP-10/IL-10 ratios in unstimulated plasma differed significantly between patients and EC, which can provide means to identify M. leprae infection. Thus, the LFAs are low-tech, robust assays that can be applied in resource-poor settings measuring immunity to M. leprae and can be used as tools for early diagnosis of leprosy leading to timely treatment and reduced transmission.